235 related articles for article (PubMed ID: 17515522)
21. Development of multiple basal cell carcinomas in mycosis fungoides treated with oral bexarotene.
Calzavara-Pinton P; Leali C; Venturini M; Sala R; Zane C
Eur J Dermatol; 2007; 17(4):341-2. PubMed ID: 17540649
[No Abstract] [Full Text] [Related]
22. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
[TBL] [Abstract][Full Text] [Related]
23. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Scarisbrick JJ; Morris S; Azurdia R; Illidge T; Parry E; Graham-Brown R; Cowan R; Gallop-Evans E; Wachsmuth R; Eagle M; Wierzbicki AS; Soran H; Whittaker S; Wain EM
Br J Dermatol; 2013 Jan; 168(1):192-200. PubMed ID: 22963233
[TBL] [Abstract][Full Text] [Related]
24. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
Singh F; Lebwohl MG
J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
[TBL] [Abstract][Full Text] [Related]
25. Oral bexarotene in the treatment of cutaneous T-cell lymphoma.
Wong SF
Ann Pharmacother; 2001 Sep; 35(9):1056-65. PubMed ID: 11573857
[TBL] [Abstract][Full Text] [Related]
26. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
Guitart J
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
[TBL] [Abstract][Full Text] [Related]
27. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
Brennand S; Sutton VR; Biagi J; Trapani JA; Westerman D; McCormack CJ; Seymour JF; Kennedy G; Prince HM
Br J Dermatol; 2005 Jun; 152(6):1199-205. PubMed ID: 15948982
[TBL] [Abstract][Full Text] [Related]
28. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
29. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Geskin L
Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
[TBL] [Abstract][Full Text] [Related]
30. Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience.
Heald PW; Perez MI; Christensen I; Dobbs N; McKiernan G; Edelson R
Yale J Biol Med; 1989; 62(6):629-38. PubMed ID: 2534648
[TBL] [Abstract][Full Text] [Related]
31. Aggressive squamous cell carcinomas in patients treated with extracorporeal photopheresis for cutaneous T-cell lymphoma.
Nehal KS; Green KB; Lim HW
Arch Dermatol; 1995 Oct; 131(10):1211-2. PubMed ID: 7574848
[No Abstract] [Full Text] [Related]
32. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis.
Knobler R; Duvic M; Querfeld C; Straus D; Horwitz S; Zain J; Foss F; Kuzel T; Campbell K; Geskin L
Photodermatol Photoimmunol Photomed; 2012 Oct; 28(5):250-7. PubMed ID: 22971190
[TBL] [Abstract][Full Text] [Related]
33. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials.
Prince HM; McCormack C; Ryan G; Baker C; Rotstein H; Davison J; Yocum R
Australas J Dermatol; 2001 May; 42(2):91-7. PubMed ID: 11309029
[TBL] [Abstract][Full Text] [Related]
34. Metastasizing squamous cell carcinomas in a patient treated with extracorporeal photopheresis for cutaneous T-cell lymphoma.
Hoetzenecker W; Benedix F; Woelbing F; Yazdi A; Breuninger H; Röcken M; Berneburg M
Acta Derm Venereol; 2007; 87(5):445-6. PubMed ID: 17721661
[No Abstract] [Full Text] [Related]
35. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.
Heald P; Mehlmauer M; Martin AG; Crowley CA; Yocum RC; Reich SD;
J Am Acad Dermatol; 2003 Nov; 49(5):801-15. PubMed ID: 14576658
[TBL] [Abstract][Full Text] [Related]
36. Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma.
Demierre MF; Tien A; Miller D
Arch Dermatol; 2005 Mar; 141(3):325-30. PubMed ID: 15781673
[TBL] [Abstract][Full Text] [Related]
37. Follicular mycosis fungoides: successful treatment with oral bexarotene.
Shistik G; Scalf LA; Fenske N; Glass LF
J Drugs Dermatol; 2004; 3(3):301-4. PubMed ID: 15176165
[TBL] [Abstract][Full Text] [Related]
38. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome.
Tsirigotis P; Pappa V; Papageorgiou S; Kapsimali V; Giannopoulou V; Kaitsa I; Girkas K; Papageorgiou E; Stavrianeas N; Economopoulos T; Dervenoulas J
Br J Dermatol; 2007 Jun; 156(6):1379-81. PubMed ID: 17459033
[No Abstract] [Full Text] [Related]
39. Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma.
Dippel E; Schrag H; Goerdt S; Orfanos CE
Lancet; 1997 Jul; 350(9070):32-3. PubMed ID: 9217723
[No Abstract] [Full Text] [Related]
40. Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.
Musolino A; Panebianco M; Zendri E; Santini M; Di Nuzzo S; Ardizzoni A
Br J Haematol; 2009 Apr; 145(1):84-6. PubMed ID: 19208096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
